Holen Sie sich die Stockscreener-App
7.91
30.31%
-3.44
Handel nachbörslich:
8.08
0.17
+2.15%
Schlusskurs vom Vortag:
$11.35
Offen:
$9.75
24-Stunden-Volumen:
3.73M
Relative Volume:
11.73
Marktkapitalisierung:
$146.55M
Einnahmen:
$1.54M
Nettoeinkommen (Verlust:
$-78.54M
KGV:
-1.3232
EPS:
-5.978
Netto-Cashflow:
$-64.50M
1W Leistung:
-13.55%
1M Leistung:
-21.37%
6M Leistung:
-33.42%
1J Leistung:
+6.89%
1-Tages-Spanne:
$7.73
$10.00
1-Wochen-Bereich:
$7.73
$12.88
52-Wochen-Spanne:
$6.72
$20.56
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Firmenname
Corbus Pharmaceuticals Holdings Inc
Sektor
Branche
Telefon
617-963-0103
Adresse
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
7.91 | 210.29M | 1.54M | -78.54M | -64.50M | -5.978 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Eingeleitet | Wedbush | Outperform |
| 2024-07-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-06-26 | Eingeleitet | B. Riley Securities | Buy |
| 2024-06-03 | Bestätigt | Oppenheimer | Outperform |
| 2024-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-03-06 | Hochstufung | Jefferies | Hold → Buy |
| 2020-09-08 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-09-08 | Herabstufung | Jefferies | Buy → Hold |
| 2020-09-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-07-07 | Eingeleitet | ROTH Capital | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-03-26 | Eingeleitet | Nomura | Buy |
| 2019-04-05 | Eingeleitet | Jefferies | Buy |
| 2019-03-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-01-11 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-12-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-10-24 | Eingeleitet | B. Riley FBR | Buy |
| 2018-01-19 | Eingeleitet | Raymond James | Outperform |
| 2017-12-14 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-11-08 | Bestätigt | Noble Financial | Buy |
| 2017-09-29 | Fortgesetzt | Noble Financial | Buy |
| 2017-03-30 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-11 | Bestätigt | Noble Financial | Buy |
Alle ansehen
Corbus Pharmaceuticals Holdings Inc Aktie (CRBP) Neueste Nachrichten
Corbus Pharmaceuticals (CRBP) Reports Promising Data on CRB-701 Trial - GuruFocus
Corbus Pharmaceuticals Stock (CRBP) Opinions on Updated CRB-701 Cancer Data Release - Quiver Quantitative
Corbus Pharmaceuticals (CRBP) Analyst Sees Mispriced Weakness - GuruFocus
CRBP Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCOSlideshow (NASDAQ:CRBP) 2026-05-26 - Seeking Alpha
Corbus Pharma (CRBP) Faces Premarket Decline Following Phase 1/2 Trial Data - GuruFocus
Corbus Pharmaceuticals stock falls on trial data release By Investing.com - Investing.com Australia
Corbus Pharmaceuticals stock falls on trial data release - Investing.com
CRB-701 data advances Corbus (NASDAQ: CRBP) OPSCC and cervical plans - Stock Titan
Corbus slips on trial data for cancer candidate (CRBP:NASDAQ) - Seeking Alpha
CRBP: CRB-701 and CRB-913 delivered promising efficacy and safety in cancer and obesity studies - TradingView
Mizuho raises Corbus Pharmaceuticals stock price target to $44 on ASCO data confidence - Investing.com Canada
CRBP: CRB-701 demonstrates strong efficacy and safety in 2L OPSCC and cervical cancer, with registrational trials planned - TradingView
Corbus Pharmaceuticals reports updated CRB-701 phase 1/2 clinical data demonstrating robust activity in 2L oropharyngeal and cervical cancers - marketscreener.com
Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers - Yahoo Finance
Corbus Pharmaceuticals teases key ASCO cancer data, late-summer obesity readout - MSN
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Raises Target Price to $44 - Moomoo
CRBP Maintained by Mizuho -- Price Target Raised to $44.00 - GuruFocus
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Corbus (CRBP) Chief Business Officer receives RSUs and 192,300 stock options - Stock Titan
Corbus (NASDAQ: CRBP) CBO Nishant Saxena reports holding 3,500 shares - Stock Titan
Corbus Pharmaceuticals Is Maintained at Outperform by Mizuho - Moomoo
Colliers facilitates 36,471 s/f lease renewal for Corbus Pharmaceuticals - NEREJ
Mizuho raises Corbus Pharmaceuticals stock price target on ASCO preview By Investing.com - Investing.com Canada
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call - Sahm
Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout - Barchart.com
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxen - The National Law Review
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals (CRBP) grants RSUs and stock options to director - Stock Titan
Corbus Pharmaceuticals (CRBP) director granted RSUs and 12,300 stock options - Stock Titan
Corbus Pharmaceuticals (CRBP) director receives RSUs and 12,300 stock options - Stock Titan
Corbus (NASDAQ: CRBP) director Anne Altmeyer receives RSU and stock option grants - Stock Titan
Equity grants increase Corbus (CRBP) director Ben Yong’s holdings - Stock Titan
Corbus (NASDAQ: CRBP) director receives RSU and stock option grants in equity package - Stock Titan
Corbus Pharmaceuticals (CRBP) director Brent Pfeiffenberger files initial Form 3 - Stock Titan
Corbus Pharmaceuticals Appoints Nishant Saxena as Chief Business Officer and Announces Pre-ASCO 2026 Data for CRB-701 in Oncology Trials - Minichart
Corbus Pharmaceuticals Appoints First Chief Business Officer - TipRanks
Corbus Pharmaceuticals announces the appointment of Nishant Saxena as chief business officer - marketscreener.com
Corbus appoints Brent Pfeiffenberger to board with equity awards - TradingView
Corbus Pharmaceuticals Holdings, Inc. announced that it will initiate a registration study of CRB-701 in second-line treatment for head and neck squamous cell carcinoma this summer. - Bitget
Corbus (NASDAQ: CRBP) hires Nishant Saxena as CBO, plans CRB-701 data call - Stock Titan
Corbus Pharmaceuticals Announces the Appointment of Nishant - GlobeNewswire
We're Keeping An Eye On Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate - Sahm
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Understanding Momentum Shifts in (CRBP) - Stock Traders Daily
symbol__ Stock Quote Price and Forecast - CNN
Corbus Pharmaceuticals Appoints Brent Pfeiffenberger to Bd of Directors - Moomoo
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors - Sahm
Finanzdaten der Corbus Pharmaceuticals Holdings Inc-Aktie (CRBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):